Use este identificador para citar ou linkar para este item: http://tcc.fps.edu.br:80/jspui/handle/fpsrepo/310
Título: Uso da dupla antiagregação plaquetária em pacientes idosos após síndrome coronariana aguda
Autor(es): MOTA, Gabriela de Lira Pessoa
SAITO, Camila Hanae Filgueira
ALMEIDA, Mariana Cavalcanti Santos de
PINHEIRO, Ana Gabriela Souza Lima Kriger
LEÃO, Gabriela Arruda Falcão de Souza
MONTEIRO, Verônica Soares
Palavras-chave: Síndrome coronariana aguda
Dupla antiagregação plaquetária
Sangramento
Idoso
Data do documento: 2015
Resumo: OBJECTIVE: To analyze the safety profile and effectiveness of the dual antiplatelet therapy in elderly admitted with acute coronary syndrome (ACS) in a cardiology ICU /CCU of the Real Hospital Português (RHP). METHODS: Non-concurrent cohort survey with samples of 165patients older than 65 years old, who were admitted to the cardiology ICU/CCU's RHP from February 2013 to September 2014 with clinical ACS. RESULTS: Of all the subjects studied, 87 were male and 78 female. Among patients diagnosed with ACS, 30.9% attended criteria for unstable angina, 49.7% for AMI without ST segment elevation and 19.4% for AMI with ST elevation. According to CRUSADE score, 44.44% of patients had high or very high chance of bleeding,23.33% had intermediate chance of bleeding and 34.44% had low or very low chance of having bleeding and 78.79% of patients did not have any evidence of bleeding. Of the 34 (20.60%) patients with bleeding, 52,94% were rated minimum, 32,35% were rated lower and 14,70% were rated higher. CONCLUSION: The use of dual antiplatelet therapy in elderly patients after an episode of ACS proved to be safe and effective, the majority of bleeding complications were minimum, without clinical repercussions.
URI: http://tcc.fps.local:80/handle/fpsrepo/310
Aparece nas coleções:Medicina

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Uso da dupla antiagregação plaquetária.pdf457.11 kBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.